Screen Reader Mode Icon

Prioritisation of Cochrane Urology Review topics

Cochrane Urology is conducting this exercise to ensure that their resources and efforts are being used to produce high-quality evidence on systematic review topics of the utmost importance to their end-users of Cochrane reviews. The results of this exercise will guide the Group's work moving forward. The full plan for this priority setting exercise can be found on the Cochrane Urology website, here.

Prior to this survey, the Group has gathered input from our Editors to devise a list of important topics for review updates and new reviews. The Group now wants your help to prioritise amongst these topics.

If you are an individual who has been affected by a prostatic disease, a carer, health professional, guideline developer, researcher, policymaker or part of an advocacy group, we would love to hear from you by completing this survey.

Your participation is voluntary. We will collect the country, role, and affiliation of each participant since it would help us map the stakeholders we have reached. Otherwise, all responses will remain confidential and anonymous. If you wish to provide your name (optional), we will acknowledge your contribution in our report. If you wish to receive the final report of this project, you can leave your email address (optional). If you provide optional contact information, this will be handled according to the Data Protection Law 25.326 (Argentina). All data is stored in a password protected electronic format. Submission of the survey will be interpreted as your informed consent to participate. This survey takes approximately 5 to 10 minutes to complete.

The steering group of this project: Philipp Dahm (Coordinating Editor Cochrane Urology), Jae Hung Jung (Coordinating Editor Cochrane Urology Satellite – Korea), Juan Franco (Contact Editor), and Robert Lane (Managing Editor – Cochrane Urology)

If you have any questions, please contact Juan Franco

Institutional Review Board approval (IRB) Nº 0038-20: Comité de Ética de Protocolos de Investigación Universitario - Instituto Universitario Hospital Italiano de Buenos Aires – Argentina. Contact information of the IRB: (Juliana Baraldo).

You are invited to share the survey link with individuals or organisations whom you think might be interested in providing feedback.

Question Title

* 1. Which role best describes you? Check all that apply.

Question Title

* 2. Personal information

Question Title

* 3. Our current portfolio has the following outdated topics (defined as those published in a review or protocol before 2018). Which topic do you consider that needs to be completed or updated most urgently?

Question Title

* 4. These are the topics we are currently covering in our reviews and protocols.

Lower urinary tract symptoms
Non-surgical management: silodosin, physical activity, naftopidil, Phosphodiesterase inhibitors, Desmopressin (nocturia), Anticholinergics combined with alpha-blockers, 5-alpha-reductase inhibitors, Serenoa repens, Pygeum africanum, Beta-sitosterols.
Surgical management: Minimally invasive treatments (network meta-analysis) including temporary implantable nitinol device (TIND), convective radiofrequency water vapour thermal therapy (Rezum), prostatic urethral lift (PUL), prostatic arterial embolization (PAE), microwave thermotherapy (TUMT). Also: Aquablation, Bipolar versus monopolar transurethral resection of the prostate (TURP), holmium laser (HoLEP) enucleation of the prostate.
Non-pharmacological and pharmacological interventions for treating chronic prostatitis/chronic pelvic pain syndrome. Antimicrobial therapy for chronic bacterial prostatitis.

Which new topics within the scope of benign conditions of the prostate need to be addressed in a Cochrane review?

These could include the effectiveness of treatments, assessing prognostic factors or the accuracy of diagnostic tests. If possible, please include the key elements of the PICO question (population, intervention/exposure, comparison, outcome), for instance: Silodosin for the treatment of lower urinary tract symptoms in men with benign prostatic hyperplasia. You can suggest up to 5 topics (minimum = 1).

Question Title

* 5. Our editors have proposed that the following topics need to be updated or included in our portfolio of reviews. Could you please rate their importance?

  Not important at all Low importance Neutral Important Very important
β3 adrenoceptor agonists (Mirabegron) for lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH)
High-intensity focused ultrasound (HIFU) for LUTS due to BPH
Urodynamic studies for the management of BPH
Photo vaporisation for the treatment of BPH
Thulium enucleation for the treatment of BPH
Prognostic factors for the progression of LUTS
Diagnostic test accuracy of investigations for bladder outlet obstruction in men

Question Title

* 6. Please provide more information for the prioritization project
If you have any questions, please contact Juan Franco:

Thank you for your input! Please feel free to distribute this survey to your contacts. We will send you the results of this survey to those who left their email address. If you have any questions, please contact Juan Franco:
0 de 6 respondidas